Skip to main navigation Skip to search Skip to main content

Correction: Phase-3 trial of recombinant human alkaline phosphatase for patients with sepsis-associated acute kidney injury (REVIVAL) (Intensive Care Medicine, (2024), 50, 1, (68-78), 10.1007/s00134-023-07271-w)

  • on behalf of the REVIVAL investigators
  • Department of Intensive Care
  • Radboud University Nijmegen
  • University of Pittsburgh
  • AM-Pharma B.V.
  • Department of Intensive Care
  • Austin Health
  • Monash University
  • Department of Anesthesiology and Intensive Care
  • Copenhagen University Hospital–North Zealand
  • Københavns Universitet, Department of Clinical Medicine
  • University of Copenhagen
  • Department of Emergency and Critical Care Medicine
  • The University of Tokyo
  • Department of Critical Care Medicine
  • University of Calgary
  • Department of Intensive Care Medicine
  • Vall d'Hebron Research Institute
  • Intensive Care
  • CHU de Limoges
  • Department of Intensive Care Medicine
  • Aarhus University
  • Intensive Care Unit
  • Sjællands Universitetshospital
  • Department of Internal Medicine and Pediatrics
  • Ghent University
  • Belgian National Fund for Scientific Research
  • Department of Anaesthesiology and Intensive Care
  • Slagelse Hospital
  • Division of Intensive Care and Emergency Medicine
  • Innsbruck Medical University
  • Center for Critical Care Nephrology
  • Division of Nephrology
  • University of California at San Francisco
  • Department of Anesthesiology
  • University of Münster
  • University of California at San Diego
  • University of Ottawa
  • University College Dublin
  • Department of Critical Care
  • Guy's and St Thomas' NHS Foundation Trust
  • Department of Perioperative and Intensive Care
  • University of Helsinki
  • Department of Anaestesiology and Intensive Care
  • Intensive Care Unit
  • Capital & Coast District Health Board
  • Medical Research Institute of New Zealand
  • University of Melbourne

Research output: Contribution to journalComment/Letter to the editorAcademic

7 Downloads (Pure)

Abstract

After the publication of the article, we have been informed that the name of a contributor in the list of REVIVAL investigators was given incomplete. He was given as “Patrick Honore” or “Honore P” but he should have been cited as “Patrick M. Honore” or “Honore PM”. Additionally, there are two mistakes in the contributors list: “ElisabethDiltoer” should read “Elisabeth Dewaele, Marc Diltoer” and “Craig French” should be also added. The original publication and the supplementary Excel file have been updated. The Authors apologize for these mistakes.

Original languageEnglish
Pages (from-to)614-615
Number of pages2
JournalIntensive care medicine
Volume50
Issue number4
DOIs
Publication statusPublished - Apr 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Correction: Phase-3 trial of recombinant human alkaline phosphatase for patients with sepsis-associated acute kidney injury (REVIVAL) (Intensive Care Medicine, (2024), 50, 1, (68-78), 10.1007/s00134-023-07271-w)'. Together they form a unique fingerprint.

Cite this